EARLY HEARING DETECTION AND INTERVENTION VIRTUAL CONFERENCE
MARCH 2-5, 2021
(Virtually the same conference, without elevators, airplane tickets, or hotel room keys)
3/05/2019 | 3:00 PM - 3:30 PM | Implications of Expanded CI Indications: When to Refer a Child for an Evaluation | International B/C
Implications of Expanded CI Indications: When to Refer a Child for an Evaluation
While FDA criteria for pediatric cochlear implantation has not changed in almost 20 years, research is providing evidence for expanded indications. Surgeons and cochlear implant teams are routinely implanting devices off-label in children who are younger and have more hearing than what would be considered within the limits of traditional pediatric cochlear implant candidacy.
Ongoing clinical trials at The University of North Carolina are showing benefits of cochlear implantation in young children with unilateral hearing loss and/or substantial residual hearing in the ear-to-be implanted. Retrospective data are in agreement with the literature indicating cochlear implantation under 12 months of age results in better outcomes.
This presentation will describe early outcomes of cochlear implantation from three cohorts of children: those with unilateral hearing loss, those with substantial residual hearing, and those implanted under 12 months of age. The performance of children with unilateral hearing loss will be reviewed on measures of quality of life, speech understanding, hearing in noise, and localization. Preliminary benefits of electric acoustic stimulation (EAS) and full electric stimulation in children with preoperative pure tone averages of <75 dB HL will be presented. An overview of the retrospective data from our clinic and the literature supporting implantation under 12 months will also be discussed. For each of these three cohorts, guidelines for referral utilizing evidence-based practice will be provided.
Caution: Implantation under 12 months, EAS, and implantation in cases of unilateral hearing loss are not currently approved or cleared by the FDA for use with children in the US.
- Participants will be able to identify when an infant with a no response ABR should be referred for a cochlear implant evaluation.
- Participants will be able to apply evidence based research to identify pediatric candidates for cochlear implant evaluation.
- Participants will be able to describe potential benefits of implantation in children with unilateral hearing loss.
Presentation:
18878_10251LisaPark.pdf
Handouts:
Handout is not Available
Transcripts:
18878_10251LisaPark.doc
Presenters/Authors
Lisa Park
(), University of North Carolina at Chapel Hill, lisa_park@med.unc.edu;
Dr. Park is a research audiologist and Assistant Professor in the Department of Otolaryngology/Head and Neck Surgery at the University of North Carolina at Chapel Hill. She received her AuD from the University of Florida and her master’s degree from Washington University in St. Louis. Her clinical research focuses on expanding cochlear implant indications for children who are deaf and hard of hearing. She investigates optimal programming for children who are considered non-traditional pediatric cochlear implant recipients, and associated outcomes on measures of speech perception, spatial hearing, and quality of life.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Margaret Dillon
(), The University of North Carolina at Chapel Hill, mdillon@med.unc.edu;
Margaret Dillon, AuD is an Associate Professor and Director of Cochlear Implant Clinical Research in the Department of Otolaryngology/Head and Neck Surgery at the University of North Carolina at Chapel Hill. Her current research interests include expanded indications for cochlear implantation, signal coding, and optimization of the fitting of electric and acoustic technologies to maximize patient benefit.
ASHA DISCLOSURE:
Financial -
Nonfinancial -